Guiding personalised treatment for immune-mediated diseases

Our Mission:

To improve outcomes for patients by guiding treatment choices

Our Vision:

Providing the tools that guide precision medicine in inflammatory disease

Incidence of inflammatory disease is rising globally

Diseases linked to genetics and environment

Unpredictable disease course has prevented optimum treatment

Our technology predicts patient disease course, informing treatment decisions

PredictSURE® IBD test available for inflammatory bowel disease

Pipeline of tests in development

helping to deliver

The right treatment, to the right patient, at the right time.

PredictImmune is a global biotechnology company. Our technology is the result of over 15 years’ research at the University of Cambridge and guides personalised treatment of patients with immune-mediated diseases.

We are developing tools to enable better disease management and an improved quality of life for patients with chronic diseases including inflammatory bowel disease (IBD) and multiple sclerosis (MS). Our first product – PredictSURE® IBD – a prognostic test for both Crohn’s disease (CD) and ulcerative colitis (UC) is now available.

Our test

Award-winning PredictSURE IBD is the world’s first validated and CE-marked prognostic test for guiding treatment options in inflammatory bowel disease (Crohn’s disease and ulcerative colitis).

PredictSURE IBD is based upon 15 years of extensive research on gene expression profiling of CD8+ T-cells. This simple blood-based biomarker test is a major step towards precision medicine in IBD.

Stratifies adult patients by risk of frequently relapsing disease

Based on a whole blood gene expression signature

Early testing aids optimal treatment choice

Latest news, blog & events